Belvedere Trading’s Altimmune ALT Stock Holding History

Belvedere Trading’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,400	Closed	-$188K	–	902
2022 Q4	$188K	Buy	+11,400	New	+$128K	﹤0.01%	355

Other funds holding ALT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Belvedere Trading's ALT Position: Q1 2024 in Review

Belvedere Trading sold out of Altimmune (ALT) in Q1 2024, closing a stake of 16,755 shares — an estimated $188K sold.

Belvedere Trading first reported a position in ALT in Q3 2021 and held it in 3 quarters. The position peaked at $288K in Q4 2022. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

Belvedere Trading reported no remaining Altimmune position as of Q1 2024 after selling out during the quarter.
Belvedere Trading sold 16,755 Altimmune shares in Q1 2024, an estimated $188K.
Belvedere Trading first reported a position in Altimmune in Q3 2021 and held it in 3 quarters.
Belvedere Trading's Altimmune position peaked at $288K in Q4 2022.
172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.